(Q33380148)

English

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. (English)

1 reference

Europe PubMed Central

26 July 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Richard A. Larson

object named as

Richard A Larson

13

0 references

Clara D. Bloomfield

12

object named as

Clara D Bloomfield

1 reference

Europe PubMed Central

26 July 2017

Krzysztof Mrózek

6

object named as

Krzysztof Mrózek

1 reference

Europe PubMed Central

26 July 2017

Michael A Caligiuri

3

object named as

Michael A Caligiuri

1 reference

Europe PubMed Central

26 July 2017

Jonathan E Kolitz

7

object named as

Jonathan E Kolitz

1 reference

Europe PubMed Central

26 July 2017

Bayard L Powell

8

object named as

Bayard L Powell

1 reference

Europe PubMed Central

26 July 2017

4

object named as

Ben L Sanford

1 reference

Europe PubMed Central

26 July 2017

11

object named as

John Anastasi

1 reference

Europe PubMed Central

26 July 2017

author name string

Maria R Baer

1

1 reference

Europe PubMed Central

26 July 2017

Stephen L George

2

1 reference

Europe PubMed Central

26 July 2017

Sandra M Bothun

5

1 reference

Europe PubMed Central

26 July 2017

Joseph O Moore

9

1 reference

Europe PubMed Central

26 July 2017

Richard M Stone

10

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

30 June 2008

1 reference

Europe PubMed Central

26 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

26 July 2017

26

1 reference

Europe PubMed Central

26 July 2017

4934-4939

1 reference

Europe PubMed Central

26 July 2017

30

1 reference

Europe PubMed Central

26 July 2017

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

The functional relationship of the interleukins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Lymphokine-activated killer cell plus recombinant interleukin-2 therapy of erythroleukemia in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

21 June 2018

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

31 October 2018

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

31 October 2018

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

31 October 2018

Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652081

31 October 2018

Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/18591543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18591543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer cell-mediated inhibition of growth of myeloid and lymphoid clonogenic leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/18591543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites

1 reference

https://pubmed.ncbi.nlm.nih.gov/18591543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18591543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18591543

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.17.0472

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33380148&oldid=1746313180"